Status:
COMPLETED
Study Of Ispinesib In Subjects With Breast Cancer
Lead Sponsor:
GlaxoSmithKline
Conditions:
Neoplasms, Breast
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this research study is to find how breast cancer responds to the investigational drug, Ispinesib. An investigational drug is a drug that has not been approved by the Food and Drug Admin...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Stage IIIB or Stage IV breast cancer
- Previously received anthracycline and taxane therapy
- Exclusion criteria:
- Actively receiving anti-cancer therapy agent(s).
Exclusion
Key Trial Info
Start Date :
June 30 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 25 2006
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00089973
Start Date
June 30 2004
End Date
August 25 2006
Last Update
February 26 2018
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Jacksonville, Florida, United States, 32224
2
GSK Investigational Site
Indianapolis, Indiana, United States, 46202
3
GSK Investigational Site
Chapel Hill, North Carolina, United States, 27599
4
GSK Investigational Site
Pittsburgh, Pennsylvania, United States, 15213